Asset profile
Mesenchymal Precursor Cells (MPCs)
Cell therapy
Evidence outlook · lead readout
NCT00721045 · Heart Failure
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
NCT00721045: The study randomized 60 participants to three MPC dose groups or sham procedures, with participants masked to assignment. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
61 competitors in this universe: 0 direct rivals (same mechanism and indication), 1 same-class, 60 same-indication; 38 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Mesenchymal Precursor Cells (MPCs): this drug | Phase 2 | Cell therapy | Pancreatic islet cell replacement | ||
| VX-264 | Phase 1/2 | Cell therapy | Pancreatic islet cell replacement | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Ferric Carboxymaltose (Injectafer / Ferinject) | Approved | Iron Complex (iv) | Iron repletion | ||
| Ferric Derisomaltose (Monoferric / Monofer) | Approved | Iron Complex (iv) | Iron repletion | ||
| Finerenone (Kerendia) | Approved | Small molecule | Mineralocorticoid receptor | ||
| Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX) | Approved | Small molecule | NKCC2 | ||
| Furosemide (subcutaneous, SQ Innovation) (Lasix ONYU) | Approved | Small molecule | NKCC2 | ||
| Icodextrin (peritoneal Ultrafiltration) (Extraneal) | Approved | Device Solution (peritoneal Dialysis) | Peritoneal ultrafiltration | ||
| Isosorbide Dinitrate / Hydralazine (BiDil) | Approved | Small molecule | Hydralazine/isosorbide dinitrate (fixed combination) | ||
| Ivabradine (Corlanor) | Approved | Small molecule | If (funny) channel | ||
| Mavacamten (Camzyos) | Approved | Small molecule | Cardiac myosin (inhibitor) | ||
| Sacubitril / Valsartan (Entresto) | Approved | Small molecule | Neprilysin + Angiotensin II receptor (dual) | ||
| Sotagliflozin (Inpefa) | Approved | Small molecule | SGLT1/2 (dual) |
…and 46 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.